INVESTIGADORES
VAZQUEZ Elba Susana
congresos y reuniones científicas
Título:
Heme-oxygenase 1 drives metabolic fate in prostate cancer
Autor/es:
ANTICO ARCIUCH, VALERIA GABRIELA; VAZQUEZ, ELBA SUSANA; ANSELMINO, NICOLÁS; PAEZ, ALEJANDRA VERÓNICA; COTIGNOLA, JAVIER HERNÁN; GUERON, GERALDINE; CASCARDO, FLORENCIA
Lugar:
Figueira da Foz
Reunión:
Conferencia; FEBS Advanced Lecture Course on Oncometabolism; 2017
Institución organizadora:
From Conceptual Knowledge to Clinical Applications
Resumen:
Prostate cancer (PCa) is the second leading cause of cancer-associated death in men. Energetic metabolism has become a new hallmark of cancer, since variations in a single gene can orchestrate changes in metabolic pathways and confer an adaptive advantage [1]. Heme-oxygenase 1 (HO-1) exerts an antitumoral role in PCa inhibiting cell proliferation, migration, tumor growth and angiogenesis [2]. The aim of this work was to assess the role of HO-1 in the metabolic signature of PCa. By RNA-Seq we found a set of metabolic genes deregulated under pharmacological induction (hemin treatment) or genetic induction of HO-1 in PC3 cells. STAR and ATP5L2 were upregulated, while HMGCS2, PRODH and ACOT12 were downregulated. The analysis of the deregulated genes (2-fold) by Gene Ontology revealed alterations in several metabolic pathways such as steroid, proline and lipid metabolism, and ATP synthesis. Bone is the only site of PCa progression, and bone cells are able to produce factors that favor progression. However, the molecular nature of this interaction remains elusive. Our results performed on co-cultures of PC3 cells (treated or not with hemin) with Raw264.7 (pre-osteoclastic) or MC3T3 (pre-osteoblastic) cells demonstrate that HO-1 directs the metabolic fate of bone precursor cells due to the deregulation of glycolytic genes. HO-1 induction in PC3 cells downregulated PKM2 and LDHA expression in co-cultured Raw264.7 and MC3T3 cells (p< 0.05).Base on our results, we propose HO-1 as a key regulator of the metabolic status of PCa cells and a powerful mediator capable of redefining the metabolic signature of bone precursor cells, thus, favoring the establishment of a less aggressive phenotype